Genelux Corp. GNLX 深 滬
等待開盤 03-26 09:30:00 美东时间
2.65
+0.230
+9.50%
華盛通- 最 高2.66
- 今 開2.46
- 成交量 34.54万股
- 最 低 2.46
- 昨 收 2.42
- 總市值 1.19亿
- 52周最高 8.535
- 市盈率 靜 --
- 換手率 0.77%
- 52周最低 1.9875
- 委 比 57.48%
- 總股本 4471.84万
- 歷史最高 40.98
- 量 比 1.32
- 振 幅 8.26%
- 歷史最低 1.60
- 每 手 1
- 風險率 1.29%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 小摩、瑞穗等下调阿里目标价最低至164美元；达登饭店、联邦快递、林肯教育服务、Planet Labs等获多家大行上调目标价
今日重点评级关注：瑞穗：维持RELMADA THERAPEUTICS"跑赢大市"评级，目标价从10美元升至19美元；奥本海默：维持Pelthos Therapeutics"跑赢大市"评级，目标价从60美元升至62美元
03-23 13:53
Benchmark Maintains Speculative Buy on Genelux, Lowers Price Target to $20
Benchmark analyst Bruce D. Jackson maintains Genelux (NASDAQ:GNLX) with a Speculative Buy and lowers the price target from $23 to $20.
03-20 23:45
Genelux Q4 EPS $(0.24) Misses $(0.21) Estimate
Genelux (NASDAQ:GNLX) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0.21) by 12.68 percent. This is a 4 percent increase over losses of $(0.25) per share from the same
03-20 04:30
Genelux Prices ~$20M Public Offering Of 6.67M Shares At A Price Of $3/Share
Genelux Corporation ("Genelux") (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced the pricing of an underwritten public offering of 6,666,667 shares of its common stock at a price to the
01-08 22:14
Genelux Announces Interim Results From Two Ongoing Trials, Phase 1b/2 SCLC And Phase 2 VIRO-25, Evaluating Systemic Administration Of Olvi-Vec In Patients With Progressive SCLC And NSCLC
-- Interim data from 14 patients with progressive lung cancers in dose-escalation cohorts of systemically administered Olvi-Vec-primed immunochemotherapy across ongoing SCLC and NSCLC trials; enrollment ongoing –-- In
01-05 21:08
Genelux Appoints Veteran Oncologist Jason Litten as CMO
Genelux Corp. ( ($GNLX) ) has issued an update. On December 30, 2025, Genelux C...
01-03 05:30
Genelux Q3 EPS $(0.21), Inline
Genelux (NASDAQ:GNLX) reported quarterly losses of $(0.21) per share which met the analyst consensus estimate. This is a 10.53 percent decrease over losses of $(0.19) per share from the same period last year.
2025-11-06 06:05
美股大行评级 | 富国银行上调苹果目标价升至290美元；"卖出"！花旗下调NuScale Power、阿特斯太阳能评级
今日重点评级关注：摩根大通：维持Cogent Biosciences"超配"评级，目标价从30美元升至44美元；Piper Sandler：维持Vital Energy"中性"评级，目标价从16美元升至30美元
2025-10-22 10:10
Lake Street Initiates Coverage On Genelux with Buy Rating, Announces Price Target of $16
Lake Street analyst Chad Messer initiates coverage on Genelux (NASDAQ:GNLX) with a Buy rating and announces Price Target of $16.
2025-10-21 22:54
Genelux Corporation to Participate in a Fireside Chat at H.C. Wainwright Global Investment Conference
<p>Genelux Corporation announced that its President, CEO, and Chairman Thomas Zindrick, along with CFO Matt Pulisic, will participate in a fireside chat at H.C. Wainwright & Co's Annual Global Investment Conference on September 9, 2025. The session, moderated by biotech analyst Emily Bodnar, will start at 2:30 p.m. ET. Interested parties can register and view the session via the provided link, with an archived replay available for 90 days post-ev...
2025-09-02 20:01
